Powered By Bing

Shelat Lab: Publications

2019

  • Loh AHP, Stewart E, Bradley CL, Chen X, Daryani V, Stewart CF, Calabrese C, Funk A, Miller G, Karlstrom A, Krafcik F, Goshorn DR, Vogel P, Bahrami A, Shelat A, and Dyer MA. Combinatorial screening using orthotopic patient derived xenograft-expanded early phase cultures of osteosarcoma identify novel therapeutic drug combinations. Cancer Lett 442: 262-270, 2019.


2018

  • Ling, T, Maier J, Das S, Budhraja A, Bassett R, Potts MB, Shelat A, Rankovic Z, Opferman JT, and Rivas F. Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents. Eur J Med Chem 164: 391-398, 2018.

  • Stewart, E, McEvoy J, Wang H, Chen X, Honnell V, Ocarz M, Gordon B, Dapper J, Blankenship K, Yang Y, Li Y, Shaw TI,Cho JH, Wang X, Xu B, Gupta P, Fan Y, Liu Y, Rusch M, Griffiths L, Jeon J, Freeman BB 3rd, Clay MR, Pappo A, Easton J, Shurtleff S, Shelat A, Zhou X, Boggs K, Mulder H, Yergeau D, Bahrami A, Mardis, Wilson RK, Zhang J, Peng J, Downing JR, and Dyer MA. Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses. Cancer Cell 34(3): 411-426 e419, 2018.

  • Bharatham N, Slavish PJ, Shadrick WR, Young BM, and Shelat AA. The role of ZA channel water-mediated interactions in the design of bromodomain-selective BET inhibitors. J Mol Graph Model 81: 197-210, 2018.

  • Shadrick WR, Slavish PJ, Chai SC, Waddell B, Connelly M, Low JA, Tallant C, Young BM, Bharatham N, Knapp S, Boyd VA, Morfouace M, Roussel MF, Chen T, Lee RE, Guy RK, Shelat AA, and Potter PM. Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors. Bioorg Med Chem 26(1): 25-36, 2018.

  • Diouf, B, Lin W, Goktug A, Grace CRR, Waddell MB, Bao J, Shao Y, Heath RJ, Zheng JJ, Shelat AA, Relling MV, Chen T, and Evans WE. Alteration of RNA Splicing by Small-Molecule Inhibitors of the Interaction between NHP2L1 and U4. SLAS Discov 23(2): 164-173, 2018.

  • Ling T, Lang W, Feng X, Das S, Maier J, Jeffries C, Shelat A, and Rivas F. Novel vitexin-inspired scaffold against leukemia. Eur J Med Chem 146: 501-510, 2018.

  • Nimmervoll BV, Boulos N, Bianski B, Dapper J, DeCuypere M, Shelat A, Terranova S, Terhune HE, Gajjar A, Patel YT, Freeman BB, Onar-Thomas A, Stewart CF, Roussel MF, Guy RK, Merchant TE, Calabrese C, Wright KD, and Gilbertson RJ. Establishing a Preclinical Multidisciplinary Board for Brain Tumors. Clin Cancer Res 24(7): 1654-1666, 2018.


2017

  • Ortiz D, Guiguemde WA, Hammill JT, Carrillo AK, Chen Y, Connelly M, Stalheim K, Elya C, Johnson A, Min J, Shelat A, Smithson DC, Yang L, Zhu F, Guy RK, and Landfear SM.Discovery of novel, orally bioavailable, antileishmanial compounds using phenotypic screening. PLoS Negl Trop Dis 11(12): e0006157, 2017.

  • Riniker S, Landrum GA, Montanari F, Villalba SD, Maier J, Jansen JM, Walters WP, and Shelat AA. Virtual-screening workflow tutorials and prospective results from the Teach-Discover-Treat competition 2014 against malaria. F1000Res 6: 1136, 2017.

  • Smallwood HS, Duan S, Morfouace M, Rezinciuc S, Shulkin BL, Shelat A, Zink EE, Milasta S, Bajracharya R, Oluwaseum AJ, Roussel MF, Green DR, Pasa-Tolic L, and Thomas PG. Targeting Metabolic Reprogramming by Influenza Infection for Therapeutic Intervention. Cell Rep 19(8): 1640-1653, 2017.

  • Stewart E, Federico SM, Chen X, Shelat AA, Bradley C, Gordon B, Karlstrom A, Twarog NR, Clay MR, Bahrami A, Freeman BB, Xu B, Zhou X, Wu J, Honnell V, Ocarz M, Blankenship K, Dapper J, Mardis ER, Wilson RK, Downing J, Zhang J, Easton J, Pappo A, and Dyer MA. Orthotopic patient-derived xenografts of paediatric solid tumours. Nature 549(7670): 96-100, 2017.

  • Genthe JR, Min J, Farmer DM, Shelat AA, Grenet JA, Lin W, Finkelstein D, Vrijens K, Chen T, Guy RK, Clements WK, and Roussel MF. Ventromorphins: A New Class of Small Molecule Activators of the Canonical BMP Signaling Pathway. ACS Chem Biol 12(9): 2436-2447, 2017.

  • Scott D, Hammill J, Min J, Rhee D, Connelly M, Sviderskiy V, Bhasin D, Chen Y, Ong S, Chai SC, Goktug A, Huang G, Monda J, Low J, Kim HS, Paulo JA, Cannon JR, Shelat A, Chen T, Kelsall IR, Alpi AF, Pagala V, Wang X, Peng J, Singh B, Harper JW, Schulman BA, and Guy RK. Targeting an N-terminal Acetylation Dependent Protein Interaction. Nat Chem Biol 13(8): 850-857, 2017.

  • Yang J, Milasta S, Hu D, AlTahan A, Interiano R, Zhou J, Davidson J, Low J, Lin W, Bao J, Goh P, Nathwani A, Wang R, Wang Y, Ong S, Boyd V, Young B, Das S, Shelat A, Wu Y, Li Z, Zheng J, Green D, White S, Guy RK, Chen T, Davidoff A, Mishra A, and Peng J. Targeting Histone Demethylases and Myc with the Small Molecule Ciclopirox. Cancer Res 77(17): 4626-4638, 2017.

  • Verras A, Waller CL, Gedeck P, Green DV, Kogej T, Raichurkar A, Panda, M, Shelat AA, Clark J, Guy RK, Papadatos G, and Burrows J. Shared Consensus Machine Learning Models for Predicting Blood Stage Malaria Inhibition. J Chem Inf Model. 2017;57(3):445-53. Epub 2017/03/04. doi: 10.1021/acs.jcim.6b00572. PubMed PMID: 28257198.


2016

  • Twarog NR, Stewart E, Hammill CV, and Shelat AA. BRAID: A Unifying Paradigm for the Analysis of Combined Drug Action. Scientific reports. 2016;6:25523. Epub 2016/05/11. doi: 10.1038/srep25523. PubMed PMID: 27160857; PubMed Central PMCID: PMC4861905.

  • Drenberg, CD, Buaboonnam J, Orwick SJ, Hu S, Li L, Fan Y, Shelat AA, Guy RK, Rubnitz J, and Baker SD. Evaluation of artemisinins for the treatment of acute myeloid leukemia. Cancer chemotherapy and pharmacology. 2016;77(6):1231-43. Epub 2016/04/30. doi: 10.1007/s00280-016-3038-2. PubMed PMID: 27125973; PubMed Central PMCID: PMC4918815.

  • Zhang, J, Bowling JJ, Smithson D, Clark J, Jacob MR, Khan SI, Tekwani BL, Connelly M, Samoylenko V, Ibrahim MA, Zaki MA, Wang M, Hester JP, Tu Y, Jeffries C, Twarog N, Shelat AA, Walker LA, Muhammad I and Guy RK. Diversity-oriented natural product platform identifies plant constituents targeting Plasmodium falciparum. Malaria journal. 2016;15(1):270. Epub 2016/05/12. doi: 10.1186/s12936-016-1313-7. PubMed PMID: 27165106; PubMed Central PMCID: PMC4863362.

  • Twarog NR, Low JA, Currier DG, Miller G, Chen T, Shelat AA. Robust Classification of Small-Molecule Mechanism of Action Using a Minimalist High-Content Microscopy Screen and Multidimensional Phenotypic Trajectory Analysis. PLoS One. 2016;11(2):e0149439. Epub 2016/02/18. doi: 10.1371/journal.pone.0149439. PubMed PMID: 26886014; PubMed Central PMCID: PMC4757101.

  • Ling T, Gautam LN, Griffith E, Das S, Lang W, Shadrick WR, Shelat A, and Rivas F. Synthesis and evaluation of colletoic acid core derivatives. European journal of medicinal chemistry. 2016;110:126-32. Epub 2016/01/29. doi: 10.1016/j.ejmech.2016.01.027. PubMed PMID: 26820555.

  • Kovar, H, Amatruda J, Brunet E, Burdach S, Cidre-Aranaz F, de Alava E, Dirksen U, van der Ent W, Grohar P, Grunewald TG, Helman L, Houghton P, Iljin K, Korsching E, Ladanyi M, Lawlor E, Lessnick S, Ludwig J, Meltzer P, Metzler M, Mora J, Moriggl R, Nakamura T, Papamarkou T, Radic Sarikas B, Redini F, Richter GH, Rossig C, Schadler K, Schafer BW, Scotlandi K, Sheffield NC, Shelat A, Snaar-Jagalska E, Sorensen P, Stegmaier K, Stewart E, Sweet-Cordero A, Szuhai K, Tirado OM, Tirode F, Toretsky J, Tsafou K, Uren A, Zinovyev A and Delattre O. The second European interdisciplinary Ewing sarcoma research summit - A joint effort to deconstructing the multiple layers of a complex disease. Oncotarget. 2016;7(8):8613-24. Epub 2016/01/24. doi: 10.18632/oncotarget.6937. PubMed PMID: 26802024.


2015

  • Morfouace M, Nimmervoll B, Boulos N, Patel YT, Shelat A, Freeman BB, 3rd, et al. Preclinical studies of 5-fluoro-2'-deoxycytidine and tetrahydrouridine in pediatric brain tumors. Journal of neuro-oncology. 2016;126(2):225-34. Epub 2015/11/01. doi: 10.1007/s11060-015-1965-0. PubMed PMID: 26518542; PubMed Central PMCID: PMC4718940.

  • Stewart E, Federico S, Karlstrom A, Shelat A, Sablauer A, Pappo A, et al. The childhood solid tumor network: A new resource for the developmental biology and oncology research communities. Developmental biology. 2016;411(2):287-93. Epub 2015/06/13. doi: 10.1016/j.ydbio.2015.03.001. PubMed PMID: 26068307.

  • Joshi A, Iyengar R, Joo JH, Li-Harms XJ, Wright C, Marino R, Winborn, BJ, Phillips A, Temirov J, Sciarretta S, Kriwacki R, Peng J, Shelat AA, Kundu M. Nuclear ULK1 promotes cell death in response to oxidative stress through PARP1. Cell Death Differ. 2016;23(2):216-30. Epub 2015/07/04. doi: 10.1038/cdd.2015.88. PubMed PMID: 26138443; PubMed Central PMCID: PMC4716304.

  • Iconaru LI, Ban D, Bharatham K, Ramanathan A, Zhang W, Shelat AA, Zuo J, Kriwacki R. Discovery of Small Molecules that Inhibit the Disordered Protein, p27(Kip1). Scientific reports. 2015;5:15686. Epub 2015/10/29. doi: 10.1038/srep15686. PubMed PMID: 26507530; PubMed Central PMCID: PMC4623604.

  • Stewart E, Shelat A, Bradley C, Chen X, Federico S, Thiagarajan S, et al. Development and characterization of a human orthotopic neuroblastoma xenograft. Developmental biology. 2015;407(2):344-55. Epub 2015/04/12. doi: 10.1016/j.ydbio.2015.02.002. PubMed PMID: 25863122; PubMed Central PMCID: PMC4600003.

  • Morfouace M, Cheepala SB, Jackson S, Fukuda Y, Patel YT, Soghra F, Kawauchi, D, Shelat AA, Stewart CF, Sorrentino B, Schuetz J D, Roussel, M Fl. ABCG2 transporter expression impacts Group3 medulloblastoma response to chemotherapy. Cancer Res. 2015;75(18):3879-89. Epub 2015/07/23. doi: 10.1158/0008-5472.CAN-15-0030. PubMed PMID: 26199091; PubMed Central PMCID: PMC4573843.

  • Gupte A, Baker E, Wan SS, Stewart E, Loh A, Shelat AA, Gould CM, Chalk A, Taylor S, Lackovic K, Karlstrom A, Mutsaers A, Desai J, Madhamshettiwar PB, Zannetiino AC, Burns C, Huang DC, Dyer M, Simpson KJ, Walkley C. Systematic screening identifies dual PI3K and mTOR inhibition as a conserved therapeutic vulnerability in osteosarcoma. Clin Cancer Res. 2015;21(14):3216-29. Epub 2015/04/12. doi: 10.1158/1078-0432.CCR-14-3026. PubMed PMID: 25862761; PubMed Central PMCID: PMC4506243.

  • Sharma LK, Leonardi R, Lin W, Boyd VA, Goktug A, Shelat AA, et al. A High-Throughput Screen Reveals New Small-Molecule Activators and Inhibitors of Pantothenate Kinases. J Med Chem. 2015;58(3):1563-8. Epub 2015/01/09. doi: 10.1021/jm501585q. PubMed PMID: 25569308; PubMed Central PMCID: PMC4357395.


2014

  • Stewart E, Goshorn R, Bradley C, Griffiths LM, Benavente C, Twarog NR, Miller GM, Caufield W, Freeman BB 3rd, Bahrami A, Pappo A, Wu J, Loh A, Karlstrom A, Calabrese C, Gordon B, Tsurkan L, Hatfield MJ, Potter PM, Snyder SE, Thiagarajan S, Shirinifard A, Sablauer A, Shelat AA and Dyer MA. Targeting the DNA repair pathway in Ewing sarcoma. Cell Rep. 2014;9(3):829-41.

  • Jimenez-Diaz, MB, Ebert D, Salinas Y, Pradhan A, Lehane AM, Myrand-Lapierre ME, O'Loughlin KG, Shackleford DM, Justino de Almeida M, Carrillo AK, Clark JA, Dennis AS, Diep J, Deng X, Duffy S, Endsley AN, Fedewa G, Guiguemde WA, Gomez MG, Holbrook G, Horst J, Kim CC, Liu J, Lee MC, Matheny A, Martinez MS, Miller G, Rodriguez-Alejandre A, Sanz L, Sigal M, Spillman NJ, Stein PD, Wang Z, Zhu F, Waterson D, Knapp S, Shelat A, Avery VM, Fidock SA, Gamo FJ, Charman SA, Mirsalis JC, Ma H, Ferrer S, Kirk K, Angulo-Barturen I, Kyle DE, DeRisi JL, Floyd DM and Guy RK. (+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium. Proc Natl Acad Sci USA. 2014;111(50):E5455-62.

  • Yang J, Liang Q, Wang M, Jeffries C, Smithson D, Tu Y, Boulos N, Jacob MR, Shelat AA, Wu Y, Ravu RR, Gilbertson R, Avery MA, Khan IA, Walker LA, Guy RK, Li XC. UPLC-MS-ELSD-PDA as a Powerful Dereplication Tool to Facilitate Compound Identification from Small-Molecule Natural Product Libraries. J Nat Prod. 2014 Apr 25;77(4):902-9.

  • Guo K, Shelat AA, Guy RK, Kastan MB. Development of a Cell-Based, High-Throughput Screening Assay for ATM Kinase Inhibitors. J Biomol Screen. 2014 Jan 24.

  • Singh H, Shelat AA, Singh A, Boulos N, Williams RT, Guy RK. A Screening-Based Approach to Circumvent Tumor Microenvironment-Driven Intrinsic Resistance to BCR-ABL+ Inhibitors in Ph+ Acute Lymphoblastic Leukemia. J Biomol Screen. 2014 Jan;19(1):158-67.

  • Morfouace M, Shelat A, Jacus M, Freeman BB, 3rd, Turner D, Robinson S, Zindy F, Wang YD, Finkelstein D, Ayrault O, Bihannic L, Puget S, Li XN, Olson JM, Robinson GW, Guy RK, Stewart CF, Gajjar A, Roussel MF. Pemetrexed and gemcitabine as combination therapy for the treatment of group3 medulloblastoma. Cancer Cell. 2014 Apr 14;25(4):516-29.

  • Gottardo NG, Hansford JR, McGlade JP, Alvaro F, Ashley DM, Bailey S, Baker DL, Bourdeaut F, Cho YJ, Clay M, Clifford SC, Cohn RJ, Cole CH, Dallas PB, Downie P, Doz F, Ellison DW, Endersby R, Fisher PG, Hassall T, Heath JA, Hii HL, Jones DT, Junckerstorff R, Kellie S, Kool M, Kotecha RS, Lichter P, Laughton SJ, Lee S, McCowage G, Northcott PA, Olson JM, Packer RJ, Pfister SM, Pietsch T, Pizer B, Pomeroy SL, Remke M, Robinson GW, Rutkowski S, Schoep T, Shelat AA, Stewart CF, Sullivan M, Taylor MD, Wainwright B, Walwyn T, Weiss WA, Williamson D, Gajjar A. Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. Acta Neuropathol. 2014 Feb;127(2):189-201.

  • Bharatham N, Bharatham K, Shelat AA, Bashford D. Ligand Binding Mode Prediction by Docking: Mdm2/Mdmx Inhibitors as a Case Study. J Chem Inf Model. 2014 Jan 21.


2013

  • Chen X, Stewart E, Shelat AA, Qu C, Bahrami A, Hatley M, Wu G, Bradley C, McEvoy J, Pappo A, Spunt S, Valentine MB, Valentine V, Krafcik F, Lang WH, Wierdl M, Tsurkan L, Tolleman V, Federico SM, Morton C, Lu C, Ding L, Easton J, Rusch M, Nagahawatte P, Wang J, Parker M, Wei L, Hedlund E, Finkelstein D, Edmonson M, Shurtleff S, Boggs K, Mulder H, Yergeau D, Skapek S, Hawkins DS, Ramirez N, Potter PM, Sandoval JA, Davidoff AM, Mardis ER, Wilson RK, Zhang J, Downing JR, Dyer MA. Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell. 2013 Dec 9;24(6):710-24.

  • McCoy F, Darbandi R, Lee HC, Bharatham K, Moldoveanu T, Royappa G, Dodd K, Lin W, Chen SI, Tangallapally RP, Kurokawa M, Lee RE, Shelat AA, Chen T, Green DR, Harris RA, Lin SH, Fissore RA, Colbran RJ, Nutt LK. Metabolic Activation of CaMKII by Coenzyme A. Mol Cell. 2013 Oct 1.

  • Jane Tseng Y, Martin E, C GB, Shelat AA. Cheminformatics aspects of high throughput screening: from robots to models: symposium summary. J Comput Aided Mol Des. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 2013 May;27(5):443-53.

  • Vrijens K, Lin W, Cui J, Farmer D, Low J, Pronier E, Zeng FY, Shelat AA, Guy K, Taylor MR, Chen T, Roussel MF. Identification of Small Molecule Activators of BMP Signaling. PLOS ONE. 2013;8(3):e59045. PMCID: 3602516.


2012

  • Guiguemde WA, Shelat AA, Garcia-Bustos JF, Diagana TT, Gamo FJ, Guy RK. Global phenotypic screening for antimalarials. Chem Biol. 2012;19(1):116-29. PMCID: 3269778.


2011

  • Cui J, Chai SC, Shelat AA, Guy RK, Chen T. An automated approach to efficiently reformat a large collection of compounds. Curr Chem Genomics. 2011;5:42-7. PMCID: 3145259.

  • Bouck DC, Shu P, Cui J, Shelat A, Chen T. A high-content screen identifies inhibitors of nuclear export of forkhead transcription factors. J Biomol Screen. 2011;16(4):394-404. PMCID: 3536487.

  • Atkinson JM, Shelat AA, Carcaboso AM, Kranenburg TA, Arnold LA, Boulos N, et al. An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell. 2011;20(3):384-99. PMCID: 3172881.


2010

  • Tu Y, Jeffries C, Ruan H, Nelson C, Smithson D, Shelat AA, et al. Automated high-throughput system to fractionate plant natural products for drug discovery. J Nat Prod. 2010;73(4):751-4. PMCID: 2866159.

  • Smithson DC, Shelat AA, Baldwin J, Phillips MA, Guy RK. Optimization of a non-radioactive high-throughput assay for decarboxylase enzymes. Assay Drug Dev Technol. 2010;8(2):175-85. PMCID: 3098607.

  • Smithson DC, Lee J, Shelat AA, Phillips MA, Guy RK. Discovery of potent and selective inhibitors of Trypanosoma brucei ornithine decarboxylase. J Biol Chem. 2010;285(22):16771-81. PMCID: 2878083.

  • Reed D, Shen Y, Shelat AA, Arnold LA, Ferreira AM, Zhu F, et al. Identification and characterization of the first small molecule inhibitor of MDMX. J Biol Chem. 2010;285(14):10786-96. PMCID: 2856285.

  • Guiguemde WA, Shelat AA, Bouck D, Duffy S, Crowther GJ, Davis PH, et al. Chemical genetics of Plasmodium falciparum. Nature. 2010;465(7296):311-5. PMCID: 2874979.


2009

  • Shelat AA, Guy RK. A road less traveled by: exploring a decade of Ellman chemistry. Bioorg Med Chem. 2009;17(3):1088-93. PMCID: 2663904.

  • Mallari JP, Shelat AA, Kosinski A, Caffrey CR, Connelly M, Zhu F, et al. Structure-guided development of selective TbcatB inhibitors. J Med Chem. 2009;52(20):6489-93. PMCID: 2762491.


2008

  • Mallari JP, Shelat AA, Obrien T, Caffrey CR, Kosinski A, Connelly M, et al. Development of potent purine-derived nitrile inhibitors of the trypanosomal protease TbcatB. J Med Chem. 2008;51(3):545-52. PMCID: 2804034.

  • Mallari JP, Shelat A, Kosinski A, Caffrey CR, Connelly M, Zhu F, et al. Discovery of trypanocidal thiosemicarbazone inhibitors of rhodesain and TbcatB. Bioorg Med Chem Lett. 2008;18(9):2883-5. PMCID: 2435229.


2007

  • Shelat AA, Guy RK. The interdependence between screening methods and screening libraries. Curr Opin Chem Biol. 2007;11(3):244-51.

  • Shelat AA, Guy RK. Scaffold composition and biological relevance of screening libraries. Nat Chem Biol. 2007;3(8):442-6.

  • Mills NL, Shelat AA, Guy RK. Assay Optimization and Screening of RNA-Protein Interactions by AlphaScreen. J Biomol Screen. 2007;12(7):946-55.

  • Fujii N, Shelat A, Hall RA, Guy RK. Design of a selective chemical probe for class I PDZ domains. Bioorg Med Chem Lett. 2007;17(2):546-8.


2006

  • Weisman JL, Liou AP, Shelat AA, Cohen FE, Guy RK, DeRisi JL. Searching for new antimalarial therapeutics amongst known drugs. Chem Biol Drug Des. 2006;67(6):409-16. PMCID: 1592519.

  • Mackey ZB, Baca AM, Mallari JP, Apsel B, Shelat A, Hansell EJ, et al. Discovery of trypanocidal compounds by whole cell HTS of Trypanosoma brucei. Chem Biol Drug Des. 2006;67(5):355-63.

  • Arnold LA, Estebanez-Perpina E, Togashi M, Shelat A, Ocasio CA, McReynolds AC, et al. A high-throughput screening method to identify small molecule inhibitors of thyroid hormone receptor coactivator binding. Sci STKE. 2006;2006(341):pl3.


2005

  • Feng BY, Shelat A, Doman TN, Guy RK, Shoichet BK. High-throughput assays for promiscuous inhibitors. Nat Chem Biol. 2005;1(3):146-8.

  • Arnold LA, Estebanez-Perpina E, Togashi M, Jouravel N, Shelat A, McReynolds AC, et al. Discovery of small molecule inhibitors of the interaction of the thyroid hormone receptor with transcriptional coregulators. J Biol Chem. 2005;280(52):43048-55.

  • Anderson MO, Shelat AA, Guy RK. A solid-phase approach to the phallotoxins: total synthesis of [Ala7]-phalloidin. J Org Chem. 2005;70(12):4578-84.


2003

  • Yang H, Shelat AA, Guy RK, Gopinath VS, Ma T, Du K, et al. Nanomolar affinity small molecule correctors of defective Delta F508-CFTR chloride channel gating. J Biol Chem. 2003;278(37):35079-85.

  • Springsteel MF, Galietta LJ, Ma T, By K, Berger GO, Yang H, et al. Benzoflavone activators of the cystic fibrosis transmembrane conductance regulator: towards a pharmacophore model for the nucleotide-binding domain. Bioorg Med Chem. 2003;11(18):4113-20.

  • Kim JW, Seo MY, Shelat A, Kim CS, Kwon TW, Lu HH, et al. Structurally conserved amino Acid w501 is required for RNA helicase activity but is not essential for DNA helicase activity of hepatitis C virus NS3 protein. J Virol. 2003;77(1):571-82. PMCID: 140573.

  • Keatinge-Clay AT, Shelat AA, Savage DF, Tsai SC, Miercke LJ, O'Connell JD, 3rd, et al. Catalysis, specificity, and ACP docking site of Streptomyces coelicolor malonyl-CoA:ACP transacylase. Structure. 2003;11(2):147-54.